No material news briefings were available for AbbVie Inc. in the current reporting cycle. Prior cycle briefs from 2026-05-24, 2026-06-01, and 2026-06-09 each referenced AbbVie's trailing twelve-month revenue through 31 March 2026 as the primary data anchor, with no discrete corporate events or announcements cited [Brief - 2026-05-24] [Brief - 2026-06-01] [Brief - 2026-06-09].
AbbVie's trailing twelve-month revenue through 31 March 2026 stood at $62.82 billion, representing year-over-year growth of 12.43%. Net income over the same period was $3.64 billion, yielding a net margin of 5.79%. Gross margin was 67.37% and operating margin was 24.41%. EPS declined 45.83% year-over-year. The company held $9.39 billion in cash against total debt of $64.50 billion. The reported price-to-earnings ratio stood at 109.59 [SEC 10-Q - ABBV - 2026-03-31].
Institutional ownership disclosures reflect material position changes across several prominent filers. Millennium Management added 61% to its position in ABBV, while Bridgewater Associates increased its reported holding by 114% [SEC 13F - Millennium - Q1 2026] [SEC 13F - Bridgewater - Q1 2026]. Citadel reduced its position by 11% and AQR Capital reduced its position by 23% over the same reporting period [SEC 13F - Citadel - Q1 2026] [SEC 13F - AQR Capital - Q1 2026]. No insider transactions under SEC Form 4 were included in the current data set.
The prevailing macroeconomic rate environment shows the 10-year US Treasury yield at 4.47% and the 2-year yield at 4.07%, producing a normal yield curve with a spread of 40 basis points [FRED DGS10] [FRED DGS2]. This report was generated in response to the material institutional position changes identified in the most recent round of 13F disclosures detailed above.